Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Claire Clibborn"'
Autor:
Delphine Staumont‐Sallé, Sébastien Barbarot, Jean David Bouaziz, Chan Chan, Claire Clibborn, Aurélie Du‐Thanh, Claire Feeney, Alexandre Lejeune, Laurent Misery, Audrey Nosbaum, Julien Seneschal, Angèle Soria, Fan Zhang
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 3, Pp 518-530 (2023)
Abstract Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti–interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD. Dupilumab
Externí odkaz:
https://doaj.org/article/aa94d1740f72494ab514527d99321156
Autor:
Shannon Wongvibulsin, Tobias Sangers, Claire Clibborn, Yu-Chuan (Jack) Li, Nikhil Sharma, John E.A. Common, Nick J. Reynolds, Reiko J. Tanaka
Publikováno v:
JID Innovations, Vol 4, Iss 1, Pp 100236- (2024)
Externí odkaz:
https://doaj.org/article/e8c4ffcac23e495eb3518eeda5867422
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 5, Pp n/a-n/a (2022)
Abstract Atopic dermatitis is a chronic inflammatory skin disease. Patients with atopic dermatitis experience inflammatory lesions associated with intense itch and pain, which lead to sleep disturbance and poor mental health and quality of life. We r
Externí odkaz:
https://doaj.org/article/247dbf3b87e346a88c1270664242f8de
Autor:
Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, H. Chih-ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann
Publikováno v:
Immunotherapy.
What is this summary about? Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicat
Autor:
Kristian Reich, Jacob P Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P Rice, H Chih-ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann
Publikováno v:
The Lancet. 400:273-282
Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study assessed the efficacy and safety of abrocitinib versus dupilumab.This randomised, double
Autor:
Jonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, Andrew E Pink, Stephan Weidinger, Gary Chan, Irina Lazariciu, Claire Clibborn, Erman Guler
Publikováno v:
British Journal of Dermatology. 188
Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, had a superior efficacy vs. dupilumab in head-to-head randomized trials in moderate-to-severe atopic dermatitis (AD). Data on patients who switched from dupilumab to abrocitinib hav
Autor:
Daniela E. Myers, Jacob P. Thyssen, Joseph C. Cappelleri, Claire Clibborn, K Mickle, Michael C. Cameron, Marco DiBonaventura, Kyle Fahrbach, Jonathan I. Silverberg, William Romero
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Given the lack of head‐to‐head studies of systemic therapies in moderate‐to‐severe atopic dermatitis (AD), network meta‐analyses (NMAs) can provide comparative efficacy and safety data to inform clinical decision‐making. In this NMA, elig
Autor:
Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, Ileana Ionita, Fan Zhang, Hernan Valdez, Claire Clibborn, Natalie Yin
Publikováno v:
Dermatology and therapy. 12(3)
Atopic dermatitis (AD) can affect multiple body regions and is especially burdensome when involving exposed skin areas. Rapid, effective treatment of AD across body regions remains an unmet need, particularly for difficult-to-treat areas such as the
Autor:
Kristian Reich, Peter A. Lio, Robert Bissonnette, Andrew F. Alexis, Mark G. Lebwohl, Andrew E. Pink, Kenji Kabashima, Mark Boguniewicz, Roman J. Nowicki, Hernan Valdez, Fan Zhang, Marco DiBonaventura, Michael C. Cameron, Claire Clibborn
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:3228-3237.e2
Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies.To examine JADE COMPARE (NCT03720470) data using stringent efficacy end points.Adults with mo
Autor:
Claire Feeney, Aurélie Du Thanh, Jean-David Bouaziz, Angèle Soria, Audrey Nosbaum, Delphine Staumont-Sallé, Alexandre Lejeune, Fan Zhang, Julien Seneschal, Laurent Misery, Gary Chan, Sébastien Barbarot, Claire Clibborn
Publikováno v:
Annales de Dermatologie et de Vénéréologie-FMC
Annales de Dermatologie et de Vénéréologie-FMC, 2021, 1 (8), pp.A348-A349. ⟨10.1016/j.fander.2021.09.420⟩
Annales de Dermatologie et de Vénéréologie-FMC, 2021, 1 (8), pp.A348-A349. ⟨10.1016/j.fander.2021.09.420⟩
Introduction L’eosinophilie est courante dans la dermatite atopique (DA) et peut-etre associee a la severite de la DA. L’inhibiteur JAK-1 abrocitinib est en cours d’evaluation pour le traitement de la (DA) moderee a severe. Si le traitement par